63787-32-6

Basic information

• Product Name: Benzoic acid, 4-(2-methoxy-2-oxoethoxy)-
• CAS NO: 63787-32-6
• Molecular Formula: C10H10O5
• Molecular Weight: 210.186
• Mol File: 63787-32-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(2-methoxy-2-oxoethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(2-methoxy-2-oxoethoxy)-(63787-32-6)
• EPA Substance Registry System: Benzoic acid, 4-(2-methoxy-2-oxoethoxy)-(63787-32-6)

Safety Data

• Hazardous Substances Data: 63787-32-6(Hazardous Substances Data)

Upstream product

• 73620-18-5 methyl (4-formylphenoxy)acetate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 1433755-22-6 C₁₄H₁₈O₅ 
• 67-56-1 methanol 
• 19360-67-9 4-carboxymethoxy-benzoic acid 
• 63787-31-5 benzyl 4-(2-methoxy-2-oxoethoxy)benzoate 

Downstream Products

• 153395-80-3 [4-(4,5-Diphenyl-[2,4']bioxazolyl-5'-yl)-phenoxy]-acetic acid methyl ester 
• 1433755-03-3 C₁₅H₁₉NO₄ 
• 1137253-44-1 C₉H₁₁N₃O₄ 
• 190515-32-3 1-[1-(tert-Butoxycarbonyl)-4-piperidyl]-4-[[4-(methoxycarbonylmethoxy)phenyl]carbonylamino]imidazole 
• 63787-33-7 4-(methoxycarbonylmethoxy)-benzoyl chloride 

Relevant articles and documents

An Aldehyde Responsive, Cleavable Linker for Glucose Responsive Insulins

A glucose responsive insulin (GRI) that responds to changes in blood glucose concentrations has remained an elusive goal. Here we describe the development of glucose cleavable linkers based on hydrazone and thiazolidine structures. We developed linkers with low levels of spontaneous hydrolysis but increased level of hydrolysis with rising concentrations of glucose, which demonstrated their glucose responsiveness in vitro. Lipidated hydrazones and thiazolidines were conjugated to the LysB29 side-chain of HI by pH-controlled acylations providing GRIs with glucose responsiveness confirmed in vitro for thiazolidines. Clamp studies showed increased glucose infusion at hyperglycemic conditions for one GRI indicative of a true glucose response. The glucose responsive cleavable linker in these GRIs allow changes in glucose levels to drive the release of active insulin from a circulating depot. We have demonstrated an unprecedented, chemically responsive linker concept for biopharmaceuticals.

COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES

There are provided according to the invention, novel compounds of formula (I)wherein R, R, R, R, Rand Rare as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

A simple method for the preparation of monomethyl esters of dicarboxylic acids by selective esterification of the nonconjugated carboxyl group in the presence of an aromatic or conjugated carboxyl group

Various dicarboxylic acids have been converted selectively into monomethyl esters in which the nonconjugated carboxyl group is selectively esterified in the presence of an aromatic or conjugated carboxyl group at room temperature (~ 25-27°C) in methanol using a catalytic amount of thionyl chloride.